The U.S. Food and Drug Administration has rejected Chiasma Inc’s experimental drug to treat adults with a type of growth disorder, the company said on Friday. Chiasma was evaluating the drug, Mycapssa, in patients with acromegaly, a growth disorder that can result in serious illness and premature death. The Food and Drug Administration issued a […]
Following mixed clinical trial results for its osteoarthritis of the knee injectable Hydros-TA, Carbylan Therapeutics said it is suspending clinical development of the therapy.
Simmering Power Struggle Between Depomed and Hedge Fund Comes to a Boil April 15, 2016By Mark Terry, BioSpace.com Breaking News Staff A simmering power struggle between Newark, Calif.-based Depomed (DEPO), a specialty pharmaceutical company, and New York-based Starboard Value, an activist hedge fund, just went into full boil. And the case has some […]
While Seres has seen explosive headcount growth over the past year, the company is planning for more. Seres is expanding its physical footprint in Cambridge and hiring more staff.
NephroGenex disclosed in a U.S. SEC filing that it had terminated Pierre Legault as CEO and president as well as Jaikrishna Patel, the company’s chief scientific officer.
U.S. federal health regulators have proposed banning Theranos Inc founder Elizabeth Holmes from the blood-testing business for at least two years after determining that the company failed to fix deficiencies at its California laboratory, the Wall Street Journal reported on Wednesday. The Centers for Medicare and Medicaid (CMS) said in letter dated March 18 that […]
San Francisco-based Medivation has reportedly rejected a bid by Paris-based Sanofi.
Valeant’s shares fell after the company received a notice of default over failure to file its 10-k form.
A federal appeals court revived a long-running lawsuit accusing Pfizer Inc. of misleading investors about the safety of the company’s Celebrex and Bextra pain-relieving drugs.
Indian drugmakers give up a battle to copy drugs developed by Bristol-Myers Squibb and AstraZeneca, blaming lack of government support for cheap generics and Big Pharma pressure.